Germany’s Merck KGaA (MRK:DE) announced a licensing agreement with New York-based small molecule developer Inspirna.
The agreement is for ompenacrid, a first-in-class SLC6A8 blocker, and will also include other similar follow-on compounds.
Omphenacrid is currently being evaluated in a Phase II trial for second-line treatment of certain people with advanced or metastatic colorectal cancer (mCRC).
Significant improvements have been made…
This article is accessible to registered users. Register for free to read more. Your free trial gives you access to his week of exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
TRY BEFORE YOU BUY
• All the news that moves the pharmaceutical and biotech needle.
• Exclusive features, podcasts, interviews, data analysis and commentary from a global network of life science reporters.
• Receive The Pharma Letter’s daily news bulletins free forever.
become a subscriber
• Free access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legislation, executive appointments, commercial strategy, and financial results.
• Daily roundup of major events in pharma and biotechnology.
• Host monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.